Search
Powered By HealthLine
Health Tools
 Heart Healthy Diet
 Ideal Body Weight Calculator
 Diet Reviews
 Fitness and Family
 Quiz: Test Your Fitness IQ
 Exercise and Fitness Guide
 Eat Out Smart
 Healthy Cooking
 BMI Calculator
Featured Conditions
 Diet & Exercise
 Stop Smoking
 Food & Fitness
 High Blood Pressure
 Cholesterol
 Heart
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today



Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

Scientists Discover New Drug Targets for Crohn's Disease

Gene-searching method uncovered more players in painful gastrointestinal condition


Related Encyclopedia
 border=
Abdominoplasty
Acidophilus
Adhesions
Amebiasis
More...

Related Healthscout Videos
 border=
eFeed: Teaching Toddlers How to Eat
Home Remedies: All Natural Antibiotics
Meals and Multitasking: Bad Combo
Eating Away Arthritis Symptoms
More...

Related Animations
 border=
GERD
PPI Therapy
More...

Related Drug Information
 border=
Aciphex
Nexium
Prevacid
Prilosec
More...

Related News Articles
 border=
Smoking May Up Cancer Risk in Barrett's Esophagus Patients
More People Need Training in Lifesaving Epinephrine Use, Advocates Say
Health Tip: Healthier Ways to Prepare Potatoes
Female Soccer Players May Face Health Problems: Study
More...

THURSDAY, Feb. 26 (HealthDay News) -- An international team of researchers has pinpointed new genetic targets for drugs to treat Crohn's disease, a chronic and painful condition caused by inflammation of the gastrointestinal tract.

The Children's Hospital of Philadelphia-led group used a new gene-searching method, combining a statistical tool that identifies genes interacting on the same biological pathways with highly automated gene-hunting techniques that scan the whole genome.

Text Continues Below



An initial analysis was performed on DNA from 1,758 Crohn's patients and 1,480 people without the disease. All of them were of European ancestry. The analysis was repeated in three more groups, of both European and African ancestry.

"Among hundreds of known biological pathways, the one that surfaced from the analysis as being most significant included genes already known to be relevant to the biology of Crohn's disease," study leader Dr. Hakon Hakonarson, director of the Center for Applied Genomics at Children's Hospital, said in a news release from the hospital.

The interleukin 12 (IL12) pathway governs cell receptors involved in the developed of Crohn's disease. Previous research has found that monoclonal antibodies that block the IL12 receptor show some clinical success in treating Crohn's disease.

The study was published online and in the March 13 print issue of The American Journal of Human Genetics.

"As we better understand the gene pathways operating in Crohn's disease, we are uncovering more potential targets for effective drug treatments," study co-author Dr. Robert Baldassano, a pediatric gastroenterologist and director of the Center for Pediatric Inflammatory Bowel Disease at Children's Hospital, said in the same news release.

Developing targeted therapies based on gene pathways might enable doctors to tailor treatments to a patient's genetic profile, he added.

More information

The Crohn's and Colitis Foundation of American has more about Crohn's disease.



-- Robert Preidt

Copyright © 2009 ScoutNews, LLC. All rights reserved.
Last updated 2/26/2009

Related Links
 border=
From Healthscout's partner site on diet & exercise, MyDietExercise.com
QUIZ: What's your ideal body weight?
QUIZ: Check your body mass index (BMI) online!
QUIZ: Rate your carbohydrate intake




SOURCE: Children's Hospital of Philadelphia, news release, Feb. 26, 2009


HealthScout is a part of HealthCentral
About Us   Our Blog   Contact Us   Privacy Policy   Terms of Use   Site Map  
Copyright © 2001-2012. The HealthCentralNetwork, Inc. All rights reserved.
Advertising Policy   Editorial Policy Advertise With Us   Anti-Spam Policy   PR Newswire